ProStrakan CEO quits amid further Sancuso and Abstral woes
This article was originally published in Scrip
Executive Summary
ProStrakan's chief executive and director Dr Wilson Totten has resigned after the company revealed it expects to suffer up to £5 million in missed operating profit for the full year as a result of not meeting supply demands for Sancuso (granisetron), a transdermal patch for the prevention of chemotherapy-induced nausea and vomiting.